Interim report 1 January - 30 June
(Thomson Reuters ONE) - Press Release, 18 August 2009 (14 pages)BioGaia ABInterim report 1 January - 30 June 2009(Figures in brackets refer to the same period of last year)Interim report 1 January - 30 June 2009- Net sales amounted to SEK 112.4 million (72.4), an increase of SEK40.0 million (55%).- Operating profit was SEK 29.9 million (12.6), an increase of SEK17.3 million.- Profit before tax was SEK 31.3 million (13.6), an increase of SEK17.7 million.- Due to earlier cumulative loss carry forward BioGaia pays no tax.Profit after reported tax was SEK 21.6 million (22.1), a decrease ofSEK 0.5 million. The period's reported tax expense of SEK 9.7 millionrefers to a change in the deferred tax asset. Profit for thecorresponding period of last year included a tax benefit of SEK 8.5million.- Earnings per share were SEK 1.26 (1.29).- The period's cash flow from operating activities before change inworking capital was SEK 32.1 million (16.2). Total cash flow for theperiod was SEK 10.9 million (5.0). Cash and cash equivalents at 30June 2009 amounted to SEK 69.0 million.Second quarter, 1 April - 30 June 2009- Net sales for the second quarter amounted to SEK 60.2 million(36.4), an increase of SEK 23.8 million (65%) over the same period oflast year. Compared to the first quarter, net sales rose by SEK 8.0million.- Operating profit was SEK 16.6 million (5.0), an increase of SEK11.6 million.- Profit before tax was SEK 16.2 million (5.6), an increase of SEK10.6 million.- Due to earlier cumulative loss carry forward BioGaia pays no tax.Profit after reported tax was SEK 11.2 million (14.1), a decrease ofSEK 2.9 million. The period's reported tax expense of SEK 5.0 millionrefers to a change in the deferred tax asset. Profit for thecorresponding period of last year included a tax benefit of SEK 8.5million.Key events in the second quarter of 2009- Distribution agreement with InfectoPharm for the sale of BioGaia'sProbiotic drops in Germany.- Agreement with Semper for the sale of probiotic oral rehydrationsolution in Sweden and Norway.No key events have taken place after the end of the reporting period."We are seeing excellent results from our efforts, with year-on-yearsales growth of 55% for the first six months. Even if one takes intoaccount earlier than schedule deliveries for SEK 5.4 million andpositive exchange rate effects, sales are increasing verysatisfactorily. Furthermore I am very happy that we have succeeded inmaintaining our gross margins and above all in containing our fixedcosts," says Managing Director Peter Rothschild.Latest press releases from BioGaia:2009-06-30 BioGaia signs new agreement with Semper for uniqueprobiotic oral rehydration solution2009-06-11 BioGaia signs distribution agreement in Germany2009-04-23 Annual General Meeting of BioGaiaFor additional information contact:Peter Rothschild, Managing Director, telephone +46 8 - 555 293 00Jan Annwall, Deputy Managing Director, telephone +46 8 - 555 293 00http://hugin.info/86913/R/1335438/317374.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 18.08.2009 - 08:15 Uhr
Sprache: Deutsch
News-ID 4811
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 350 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Interim report 1 January - 30 June"
steht unter der journalistisch-redaktionellen Verantwortung von
BioGaia AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
